



JUL 28 2008

Mr. Allan Adler
VP, Government and Legal Affairs
Association of American Publishers
50 F Street, N.W., Suite 400
Washington, D.C. 20001

Dear Mr. Adler:

Thank you for your April 16 letter to Dr. Elias Zerhouni, Director of the National Institutes of Health (NIH), regarding the implementation of P.L. 110-161, § 218, Section 2, Division G by the NIH. You have raised a number of questions and suggestions concerning the Public Access Policy. As you know, we have recently concluded a Request for Information (RFI) on the NIH Public Access Policy that was designed to identify areas of concern and suggestions for improvement. We will include this letter with our RFI responses, and consider it in our analysis and response. We will issue our final report by September 30, 2008.

In the meantime, you will find many of your questions addressed by previously released material.

For information on copyright, please review the following information sources:

- February 9, 2005, *Federal Register* notice: <http://frwebgate1.access.gpo.gov/cgi-bin/waisgate.cgi?WAISdocID=577774374324+0+0+0&WAIAction=retrieve>
- The current NIH Public Access Policy Frequently Asked Questions: <http://publicaccess.nih.gov/FAQ.htm>
- For information about PubMed Central, Quality Control, Linkage, Repurposing, and Piracy, and Cost please see:
 - Information for Publishers: <http://www.pubmedcentral.nih.gov/about/pubinfo.html> and
 - The PubMed Central Frequently Asked Questions: <http://www.pubmedcentral.nih.gov/about/faq.html>
- For information on how NIH communicates the NIH Public Access Policy with its stakeholders: see <http://publicaccess.nih.gov/>
- For questions about Compensation and Scope, see the current NIH Public Access Policy Frequently Asked Questions: <http://publicaccess.nih.gov/FAQ.htm>

Page 2 – Mr. Allan Adler

Thank you for your questions. We look forward to your feedback on our extant guidance and to further thoughts on how to measure any possible impacts of P.L. 110-161, Section 2, Division G, Title II, § 218 on scientific publishing.

I am also sending this response to Mr. Martin Frank.

Sincerely,

A handwritten signature in black ink that reads "Norka Ruiz Bravo". The signature is written in a cursive style with a large initial 'N'.

Norka Ruiz Bravo, Ph.D.
Director
Office of Extramural Research

